Home › Companies › COGT

Cogent Biosciences, Inc.

COGT Rare disease Lead: NDA Submitted 1 Biotech Distilled article ↓

Hematology Oncology Small Molecule

Most recent annual filing: 2026-02-15

Pipeline (7 active programs)

bezuclastinib

CGT9486

Small Molecule Target: KIT D816V, KIT exon 17, KIT

Non-Advanced Systemic Mastocytosis Phase 2 oral Plexxikon
Gastrointestinal Stromal Tumor NDA Submitted oral Plexxikon
Gastrointestinal Stromal Tumors NDA Submitted Plexxikon

CGT4859

Small Molecule Target: FGFR2, FGFR3

Cholangiocarcinoma Phase 1 oral

CGT4255

Small Molecule Target: ErbB2, HER2

Undisclosed indication Phase 1 oral
Undisclosed indication Phase 1

CGT6297

Small Molecule Target: PI3Kα

Undisclosed indication Phase 1

Biotech Distilled coverage (1)

2026-04-18 Cogent Biosciences (COGT) - Scientific Deep Dive for Bezuclastlnib and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.